Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci

Open access
Pfister, Stefan, Remke, Marc, Benner, Axel, Mendrzyk, Frank, Toedt, Grischa, Felsberg, Jörg, Wittmann, Andrea, Devens, Frauke, Gerber, Nicolas U., Joos, Stefan, Kulozik, Andreas, Reifenberger, Guido, Rutkowski, Stefan, Wiestler, Otmar D., Radlwimmer, Bernhard, Scheurlen, Wolfram, Lichter, Peter, Korshunov, Andrey·2009·Journal of Clinical Oncology

Abstract

Purpose: Medulloblastoma is the most common malignant brain tumor in children. Current treatment decisions are based on clinical variables. Novel tumor-derived biomarkers may improve the risk stratification of medulloblastoma patients. Patients and Methods: A model for the molecular risk stratification was proposed from an array-based comparative genomic hybridization (array-CGH) screen (n = 80). Fluorescence in situ hybridization (FISH) analyses for chromosome arms 6q, 17p, and 17q and the MYC and MYCN loci were performed in an independent validation set (n = 260). Copy number aberrations were correlated with clinical, histologic, and survival data. Results: Gain of 6q and 17q and genomic amplification of MYC or MYCN were each associated with poor outcome in the array-CGH study (n = 80). In contrast, all patients with 6q-deleted tumors survived. Given these findings, the following hierarchical molecular staging system was defined: (1) MYC/MYCN amplification, (2) 6q gain, (3) 17q gain, (4) 6q and 17q balanced, and (5) 6q deletion. The prognostic value of this staging system was investigated by FISH analysis (n = 260). The addition of molecular markers to clinical risk factors resulted in the identification of a large proportion of patients (72 of 260 patients; 30%) at high risk for relapse and death who would be considered standard risk by application of clinical variables alone. Conclusion: Genomic aberrations in medulloblastoma are powerful independent markers of disease progression and survival. By adding genomic markers to established clinical and histologic variables, outcome prediction can be substantially improved. Because the analyses can be conducted on routine paraffin-embedded material, it will be especially feasible to use this novel molecular staging system in large multicenter clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.17.9432

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 293

Metadata

Authors
Pfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N. U., Joos, S., Kulozik, A., Reifenberger, G., Rutkowski, S., Wiestler, O. D., Radlwimmer, B., Scheurlen, W., Lichter, P., & Korshunov, A.
Venue
Journal of Clinical Oncology
Published
2009-04-01
Volume
27
Issue
10
Pages
1627-1636
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1995541594
Cited by
293
References
34
FWCI
17.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci. https://app.cochat.ai/papers/10.1200/jco.2008.17.9432
The paper
Pfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N. U., Joos, S., Kulozik, A., Reifenberger, G., Rutkowski, S., Wiestler, O. D., Radlwimmer, B., Scheurlen, W., Lichter, P., & Korshunov, A. (2009). Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.17.9432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.